



Press release 2015-04-13

## Order for three C-RAD systems from Italy

**C-RADs Italian distributor – TecnoSan S.a.s – secured an order for two Catalyst™ systems as well as one Sentinel™ 4DCT system from the Ospedale del Mare cancer clinic in Naples.**

The Catalyst will be delivered with the complete software configuration containing modules for Respiratory Gating, Patient Setup and Positioning, and Motion Monitoring, as well as interfaces to a General Electric CT and the Elekta Versa HD linear accelerators. The customer also decided on the unique audio-visual couching functionality that supports an interactive gating mode.

The cancer center is part of a newly build hospital Ospedale del Mare. The oncology department is expected to be open for patients at the beginning of 2016.

C-RAD and TecnoSan will use this site as a reference to present the products in the clinical environment to other clinics in southern Italy. Another Catalyst and Sentinel 4DCT installation are clinical operational in northern Italy.

The Catalyst and Sentinel systems offer the required technology to perform high-end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.

“We are pleased to contribute to such an important challenge for the city of Naples,” says Dr. Mattia Dell’Orsola, Sales and Marketing Manager at TecnoSan. “The C-RAD Sentinel and Catalyst systems allow sophisticated radiation treatments with much greater safety. Moreover with this installation, the advanced treatment based on C-RAD technology will finally be available to patients in southern Italy.”

“Announcing this order from Italy shows the beginning of a hopefully positive trend for southern Europe” says Tim Thurn, CEO of C-RAD. “For the last two years these economies have been suffering from financial constraints. It is my expectation that investments in medical equipment will recover this year and the Italian market will continue to contribute to our success. I am very much looking forward to include this new reference site into our network of clinical users.”

### *About C-RAD*

*C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 31. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in*



*China. C-RAD holds 29% of the shares in laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed on NASDAQ OMX.*

*For more information on C-RAD, please visit [www.c-rad.com](http://www.c-rad.com).*

**For further information:**

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email [investors@c-rad.com](mailto:investors@c-rad.com)

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).